The effect of curcumin (turmeric) on Alzheimer’s disease: An overview

Shrikant Mishra, Kalpana Palanivelu
Department of Neurology, VA/USC 16111, Sepulveda, CA, USA

Abstract

This paper discusses the effects of curcumin on patients with Alzheimer’s disease (AD). Curcumin (Turmeric), an ancient Indian herb used in curry powder, has been extensively studied in modern medicine and Indian systems of medicine for the treatment of various medical conditions, including cystic fibrosis, haemorrhoids, gastric ulcer, colon cancer, breast cancer, atherosclerosis, liver diseases and arthritis. It has been used in various types of treatments for dementia and traumatic brain injury. Curcumin also has a potential role in the prevention and treatment of AD. Curcumin as an antioxidant, anti-inflammatory and lipophilic action improves the cognitive functions in patients with AD. A growing body of evidence indicates that oxidative stress, free radicals, beta amyloid, cerebral deregulation caused by bio-metal toxicity and abnormal inflammatory reactions contribute to the key event in Alzheimer’s disease pathology. Due to various effects of curcumin, such as decreased Beta-amyloid plaques, delayed degradation of neurons, metal-chelation, anti-inflammatory, antioxidant and decreased microglia formation, the overall memory in patients with AD has improved. This paper reviews the various mechanisms of actions of curcumin in AD and pathology.

Keywords

Alternative approach to Alzheimer’s, beta amyloid plaques, curcumin, curcumin and dementia, epidemiology, turmeric

Introduction

Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease. It is characterized by progressive cognitive deterioration together with declining activities of daily living and behavioral changes. It is the most common type of pre-senile and senile dementia. According to the World Health Organization (WHO), 5% of men and 6% of woman of above the age of 60 years are affected with Alzheimer’s type dementia worldwide.[1] In India, the total prevalence of dementia per 1000 people is 33.6%, of which AD constitutes approximately 54% and vascular dementia constitutes approximately 39%. AD affects approximately 4.5 million people in the United States or approximately 10% of the population over the age of 65, and this number is projected to reach four times by 2050. The frequency increases to 50% by the age of 80 years. Every year more than $100 billion is spent for health care in the U.S. to treat AD in primary care settings alone.

Neuropathology of AD: The neuropathological process consists of neuronal loss and atrophy, principally in the temporoparietal and frontal cortex, with an inflammatory response to the deposition of amyloid plaques and an abnormal cluster of protein fragments and tangled bundles of fibres (neurofibrillary tangles). Neurotic plaques are relatively insoluble dense cores of 5-10 nm thick amyloid fibrils with a pallor staining “halo” surrounded by dystrophic neuritis, reactive astrocytes and activated microglia. There is an increased presence of monocytes/macrophages in the cerebral vessel wall and reactive or activated microglial cells in the adjacent parenchyma.[2,3] The main protein component of amyloid in AD is the 39-42 amino acid (beta) amyloid peptide (A-beta) [Figure 1].

Figure 1: Neuritic plaques are one of the characteristic structural abnormalities found in the brains of Alzheimer patients
Curcumin
Curcumin (Curcuma longa - Haldi) is the source of the spice Turmeric [Figure 2] and is used in curries and other spicy dishes from India, Asia and the Middle East. Similar to many other herbal remedies, people first used curcumin as a food and later discovered that it also had impressive medicinal qualities. It has been used extensively in Ayurveda (Indian system of Medicine) for centuries as a pain relieving, anti-inflammatory agent to relieve pain and inflammation in the skin and muscles. It has also proven to have anti-cancer properties.\(^4,5\) Curcumin holds a high place in Ayurvedic medicine as a “cleanser of the body,” and today, science is finding a growing list of diseased conditions that can be healed by the active ingredients of turmeric.\(^6\)

The Plant
Botanical name: Curcuma longa; Family: Zingiberaceae, the ginger family. Turmeric is a sterile plant and does not produce any seeds [Figure 2]. The plant grows up to 3-5 ft tall and has dull yellow flowers. The underground rhizomes or roots of the plant are used for medicinal and food preparation. The rhizome is an underground stem that is thick and fleshy ringed with the bases of old leaves. Rhizomes are boiled and then dried and ground to make the distinctive bright yellow spice, turmeric.

Turmeric History: Probably originating from India, turmeric has been used in India for at least 2500 years. It is most common in southern Asia and particularly in India. Turmeric was probably cultivated at first as a dye and later on it was used as cosmetic and as an auspicious and aromatic food substance. It possesses antiseptic, anti-inflammatory detoxifying properties as well as carminative properties. Turmeric has a long history of medicinal use in South Asia and was widely used in Ayurvedic, Siddha and Unani systems. It is thought to be a hybrid selection and vegetative propagation of wild turmeric (Curcuma aromatica), which is native to India, Sri Lanka and the eastern Himalayas and some other closely related species.

Curcumin and Alzheimer’s Disease
Worldwide, there are over 1000 published animal and human studies, both in vivo and in vitro in which the effects of curcumin on various diseases have been examined. Studies include epidemiological, basic and clinical research on AD.

Bio Chemical properties

| Property name                                      | Property value                                      | Notes/description                                                                 |
|---------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------|
| Molecular formula                                 | C₂₁H₂₀O₆                                            | Molecular formula for curcumin. Curcumin is the main curcuminoid and it is        |
| Main curcuminoids present in turmeric             | Curcumin Demethoxycurcumin Bisdemethoxycurcumin     | considered to be most active constituent. The curcuminoid are polyphenols and are |
| Tautomeric forms of curcumin                      | keto and enol\(^7\) [Figure 2-3] It can also exist as cis-trans isomeric forms.\(^8\) | responsible for the yellow color of turmeric. The enol form is more energetically  |
| E number                                          | E100                                                | stable in the solid phase and in solution. Curcumin can be used for boron        |
| Melting point                                     | 183°C (361 K)                                       | quantification in the so-called curcumin method. It reacts with boric acid        |
| Color                                             | It can appears as bright yellow to orange powder    | forming a red color compound known as rosocyanine. It has photo-biological and     |
| Molar mass                                         | 368.38 g/mol                                        | photosensitizing activity. As curcumin is brightly colored, it may be used       |
| Systemic name                                      | (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione | as a food color. It is often used as food additive. Other names for the curcumin  |

Figure 2: (2a) Turmeric, (2b) Turmeric plant, (2c) Keto and enol form of curcumin
Epidemiological Studies

Various studies and research results indicate a lower incidence and prevalence of AD in India. The prevalence of AD among adults aged 70-79 years in India is 4.4 times less than that of adults aged 70-79 years in the United States. Researchers investigated the association between the curry consumption and cognitive level in 1010 Asians between 60 and 93 years of age. The study found that those who occasionally ate curry (less than once a month) and those who more than once a month) performed better on a standard test (MMSE) of cognitive function than those who ate curry never or rarely.

Mechanism of action of curcumin on Alzheimer’s disease:
The process through which AD degrades the nerve cells is believed to involve certain properties: inflammation, oxidative damage and most notably, the formation of beta-amyloid plaques, metal toxicity [Figure 3]. There have been several studies on effects of curcumin on AD. Outlined below are some of the studies and their conclusions.

Effects of Curcumin on Macrophages

A study conducted at UCLA found that curcumin may help the macrophages to clear the amyloid plaques found in Alzheimer’s disease. Macrophages play an important role in the immune system. They help the body to fight against foreign proteins and then effectively clear them. Curcumin was treated with macrophages in blood taken from nine volunteers: six AD patients and three healthy controls. Beta amyloid was then introduced. The AD patients, whose macrophages were treated with curcumin, when compared with patients whose macrophages were not treated with curcumin, showed an improved uptake and ingestion of the plaques. Thus, curcumin may support the immune system to clear the amyloid protein.

Curcumin on glial cells: Recent histological studies reveal the presence of activated microglia and reactive astrocytes around A-beta plaques in brains from patients with AD. The chronic activation of microglia secretes cytokines and some reactive substances that exacerbate A-beta pathology. So neuroglia is an important part in the pathogenesis of AD. Curcumin has a lipophilic property and can pass through all cell membranes and thus exerts its intracellular effects. Curcumin has anti-proliferative actions on microglia. A minimal dose of curcumin affects neuroglial proliferation and differentiation. Its inhibition of microglial proliferation and differentiation were studied and researched by the University of Southern California Los Angeles (UCLA). Researchers using doses of 4, 5, 10, 15, 20 microM concentration of curcumin in C-6 rat glioma 2B-clone cells, a mixed colony of both neuroglial cells in a six-day trial, showed that curcumin dose dependently stops the proliferation of neuroglial cells, by differentiate into a mature cell or undergo apoptosis. It inhibits neuroglial cells proliferation dose dependently (i.e.) higher the concentration, the greater the inhibition. It has shown to decrease the glutamine synthetase (GS) assay, a marker enzyme for astrocytes.

Curcumin as an Anti Inflammatory in Alzheimer’s

One of the important pathogenesis in Alzheimer’s disease is the chronic inflammation of nerve cells. Several studies have demonstrated the associated inflammatory changes such as microgliosis, astrocytosis and the presence of pro-inflammatory substances that accompany the deposition of amyloid-β (Aβ) peptide. Patients with the prolonged use of certain nonsteroidal anti-inflammatory (NSAID) drugs such as ibuprofen have been shown to have a reduced risk of developing the symptoms of AD; however, the chronic use of NSAID can cause a toxic effect on the kidneys, liver and GI track. Curcumin has a potent anti-inflammatory effect. Through its various anti-inflammatory effects, it may have a role in the cure of AD. Curcumin inhibits Aβ-induced expression of Egr-1 protein and Egr-1 DNA-binding activity in THP-1 monocyctic cells. Studies have shown the role of Egr-1 in amyloid peptide-induced cytotoxicity gene expression in monocytes. By inhibition of Egr-1 DNA-binding activity by curcumin, it reduces the inflammation. The chemotaxis of monocytes, which can occur in response to chemokines from activated microglia and astrocytes in the brain, can be decreased by curcumin.

Curcumin is found to inhibit cyclooxygenase (COX-2), phospholipases, transcription factor and enzymes

Figure 3: Different mechanisms of action of curcumin in AD
involved in metabolizing the membrane phospholipids into prostaglandins. The reduction of the release of ROS by stimulated neutrophils, inhibition of AP-1 and NF-Kappa B inhibit the activation of the pro-inflammatory cytokines TNF (tumor necrosis factor)-alpha and IL (interleukin)-1 beta.\textsuperscript{[15,16]} Overall, curcumin decreases the main chemicals for inflammation and the transcription of inflammatory cytokines. Curcumin inhibits intracellular IL-12 p40/p70 and IL-12 p70 expression. The exposure to curcumin also impaired the production of pro-inflammatory cytokines (IL-1, IL-6 and TNF-). These studies indicate a potent inhibitor of pro-inflammatory cytokine production by curcumin and it may differ according to the nature of the target cells.

**Curcumin as an Anti-oxidant**

Curcumin inhibits the activity of AP-1, a transcription factor involved in expression of amyloid, which is linked to AD. Curcuminoids are proven to have strong antioxidant action demonstrated by the inhibition of the formation and propagation of free radicals. It decreases the low-density lipoprotein oxidation and the free radicals that cause the deterioration of neurons, not only in AD but also in other neuron degenerative disorders such as Huntington's and Parkinson's disease.\textsuperscript{[16]} In one study, curcuma oil (500 mg Kg\(^{-1}\) i.p.) was given 15 min before 2 h middle cerebral artery occlusion, followed by 24 h reflow in rats. This significantly diminished the infarct volume, improved neurological deficit and counteracted oxidative stress.\textsuperscript{[17]}

A study conducted at Nanjing Medical University (China) showed that a single injection of curcumin (1 and 2 mg/kg, i.v.) after focal cerebral ischemia/reperfusion in rats significantly diminished the infarct volume, improved neurological deficit, decreased mortality and reduced the water content in the brain.\textsuperscript{[18]}

Curcumin has powerful antioxidant and anti-inflammatory properties; according to the scientists, these properties believe help ease Alzheimer's symptoms caused by oxidation and inflammation.\textsuperscript{[19]} A study conducted at Jawaharlal Nehru University (India) demonstrated that the administration of curcumin significantly reduced lipid peroxidation and lipofuscin accumulation that is normally increased with aging.\textsuperscript{[20]} It also increased the activity of superoxide dismutase, sodium-potassium ATPase that normally decreased with aging. In another study, curcumin has been shown to protect the cells from betaA (1-42) insult through antioxidant pathway.\textsuperscript{[21]} Curcumin protects brain mitochondria against various oxidative stress. Pre-treatment with curcumin protects brain mitochondria against peroxynitrite (a product of the reaction of nitric oxide with superoxide) a potent and versatile oxidant that can attack a wide range of cells \textit{in vitro} by direct detoxification and \textit{in vivo} by the elevation of total cellular glutathione levels.\textsuperscript{[22]}

**Curcumin on Haemoxygenase Pathway**

Natural antioxidant curcumin has been identified as a potent inducer of hemoxygenase, a protein that provides efficient cytoprotection against various forms of oxidative stress. By promoting the inactivation of Nrf2-keap1 complex and increased binding to no-1ARE, curcumin induces hemoxygenase activity. The incubation of astrocytes with curcumin at a concentration that promoted hemoxygenase activity resulted in an early increase in reduced glutathione, followed by a significant elevation in oxidized glutathione content.\textsuperscript{[23-25]} Glutathione is an important water-phase antioxidant and essential cofactor for antioxidant enzymes protecting the mitochondria against endogenous oxygen radicals. Its level reflects the free radical scavenging capacity of the body. GSH depletion leads to tissue damage due to lipid peroxidation and oxidative damage.

**Beta-Amyloid Plaques**

The most prominent characteristic feature in AD is the presence of beta-amyloid plaques. These plaques are basically an accumulation of small fibers called beta amyloid fibrils. Because the deposition of beta-amyloid protein is a consistent pathological hallmark of brains affected by AD, the inhibition of A-beta generation, prevention of A-beta fibril formation, destabilization of pre-formed A-beta would be an attractive therapeutic strategy for the treatment of AD. The levels of beta-amyloid in AD mice that were given low doses of curcumin were decreased by around 40% in comparison to those that were not treated with curcumin. In addition, low doses of curcumin also caused a 43% decrease in the so-called “plaque burden” that these beta-amyloid have on the brains of AD mice. Surprisingly low doses of curcumin given over longer period were actually more effective than high doses in combating the neurodegenerative process of AD.\textsuperscript{[26]} At higher concentration, curcumin binds to amyloid beta and blocks its self assembly. The key chemical features in amyloid beta are the presence of two aromatic end groups and any alterations in these groups has profound effect on its activity.

Because of the lipophilic nature of curcumin, it crosses the blood brain barrier and binds to plaques. Curcumin was a better A-beta 40 aggregation inhibitor and it destabilizes the A-beta polymer. In \textit{in vitro} studies, curcumin inhibits aggregation as well as disaggregates to form fibrillar A-beta 40. A Japanese study showed that using fluorescence spectroscopic analysis with thioflavin T and electron microscopic studies, curcumin
destabilizes the fA-beta(1-40) and fA-beta(1-42) as well as their extension. Curcumin-derived isoxazoles and pyrazoles bind to the amyloid beta peptide (Abeta) and inhibit amyloid precursor protein (APP) metabolism. Curcumin given to APPswe/PS1dE9 mice for 7 days crosses the blood-brain barrier as demonstrated by multi-photon microscopy and reduces the existing senile plaques. In another study, curcumin has been shown to increase the phagocytosis of amyloid-beta, effectively clearing them from the brains of patients with AD.

**Metal Chelation**

Studies showed that metals can induce A-beta aggregation and toxicity and are concentrated on Alzheimer’s brain. Chelators’ desferroxamine and cliquinoil have exhibited anti-Alzheimer’s effects. A study at Capital University Beijing demonstrated the toxicity of copper on neurons. A greater amount of H2O2 was released when copper (2)-A(beta)-40 complexes were added to the xanthene oxidase system. Copper was bound to A(beta)1-40 and was observed by electron paramagnetic resonance spectroscopy. In addition, copper chelators could cause a structural transition of A(beta). There was an increase on beta sheet as well as alpha-helix when copper was introduced. Another study reveals that copper and zinc bind A-beta inducing aggregation and give rise to reactive oxygen species. There was a conformational change from beta sheet to alpha helix followed by peptide oligomerization and membrane penetration, when copper (or) zinc is added to A-beta in a negatively charged lipid environment. Brain iron deregulation and its association with amyloid precursor protein plaque formation are implicated in the pathology of AD.

Curcumin, by interaction with heavy metals such as cadmium and lead, prevents neurotoxicity caused by these metals. The intraperitoneal injection of lead acetate in rats in the presence of curcumin was studied microscopically. The results show lead-induced damage to neurons was significantly reduced in rats injected with curcumin. A study at Chinese University of Hong Kong showed that by using spectrophotometry, the curcumin effectively binds to copper, zinc and iron. In addition, curcumin binds more effectively with redox-active metals such as iron and copper than the redox-inactive zinc. It is suggested that curcumin suppresses inflammatory damage by preventing metal induction of NF-kappa.

**Cholesterol Lowering Effect**

High-fat diets and increased blood cholesterol are linked to increased amyloid plaques by the intracellular accumulation of cholestryl esters. Researchers believe that by inhibiting cholesterol formation and decreasing serum peroxides, curcumin might exert beneficial effects on AD.

**Safety**

**Oral bioavailability:** Curcumin has poor bioavailability. Because curcumin readily conjugated in the intestine and liver to form curcumin glucuronides. In a clinical trial conducted in Taiwan, serum curcumin concentrations peaked one to two hours after an oral dose. Peak serum concentrations were 0.5, 0.6 and 1.8 micromoles/L at doses of 4, 6 and 8 g/day respectively. It is also measured in urine at a dose of 3.6 g/day. Absorption is poor following ingestion in mice and rats. 38% to 75% of an ingested dose of curcumin is excreted in the feces. Absorption appears to be better with food. Curcumin crosses the blood brain barrier and is detected in CSF.

**Side Effect**

No apparent side effects have been reported thus far. GI upset, chest tightness, skin rashes, swollen skin are said to occur with high dose. A few cases of allergic contact dermatitis from curcumin have been reported.

The chronic use of curcumin can cause liver toxicity. For this reason, turmeric products should probably be avoided by individuals with liver disease, heavy drinkers and those who take prescription medications that are metabolized by liver. Curcumin was found to be pharmacologically safe in human clinical trials with doses up to 10 g/day. A phase 1 human trial with 25 subjects using up to 8000 mg of curcumin per day for three months found no toxicity from curcumin.

**Interaction**

Curcumin is said to interact with certain drugs such as blood thinning agents, NSAIDs, reserpine. Co-supplementation with 20 mg of piperine (extracted from black pepper) significantly increase the bioavailability of curcumin by 2000%.

**Contraindication**

Curcumin is not recommended for persons with biliary tract obstruction because it stimulates bile secretion. It is also not recommended for people with gallstones, obstructive jaundice and acute biliary colic. Curcumin supplementation of 20-40 mg have been reported to increase gallbladder contractions in healthy people.

**Human**

Epidemiological studies have shown that prevalence of AD is 4.4 lower amongst Indian Asians as compared to people of western origin. Dementia incidence in
**Experimental studies: Statistical significance**

| Subject studies | Vitro | Vivo |
|-----------------|-------|------|
| Mice | Curcumin was a A-beta40 aggregation inhibitor prevented A-beta42 oligomer formation and toxicity between 0.1-1.0 microM. These changes were statistically significant $p$ value ($p < 0.001$)$^{[25]}$ | Given to aged Tg2576 mice with advanced amyloid accumulation, curcumin reduced amyloid levels and plaque burden reduction in plaque burden ($p > 0.0001$)$^{[24]}$ |
| Rat | The middle-aged rats ($n = 10$) that were fed with various diets were evaluated for spatial memory deficits in a standard Morris water maze, showed that A-infused rats fed with curcumin (500 ppm) showed reduced path length and latency in finding the hidden platform and increase in spatial memory. ($p < 0.001$). The synotopsin loss was significantly reduced in A-infused rats fed curcumin ($p < 0.05$) and Curcumin and ibuprofen reduced microgial area in both cortical layers ($p < 0.05$) | (1) Rats injected intraperitoneally with lead acetate (20 mg/kg) in the presence and absence of curcumin (30 mg/kg) were compared. Lead-induced damage to neurons significantly reduced ($p < 0.001$) when studied microscopically to determine the extent of lead-induced damage to the cells in the hippocampus.$^{[26]}$ (2) 500 ppm of Curcumin in the diet for 4 weeks reduced the oxidative damage in rats ($n = 8$/group) with mild fluid percussion brain injury. Curcumin supplementation counteracted the impairment in cognition caused by traumatic brain injury with ($p < 0.05$).$^{[27]}$ |
| Planaria | Curcumin improved the memory curves in planaria with correlation coefficient of 0.97.$^{[44]}$ | |

western countries ($P < 0.21$) and East Asian countries were lower than that of Europe ($P < 0.0004$)$^{[49]}$

**Clinical -Vivo:** Blood from six patients with AD and three healthy controls was taken and the macrophage cells were isolated. After treatment of macrophages with curcuminoids, Aβ uptake by macrophages of three of the six AD patients was found to have significantly increased ($P < 0.001$ to 0.081)$^{[11]}$

Five animal and two human studies showed statistically significant $P$ values.

**Conclusion**

Based on the main findings detailed above, curcumin will lead to a promising treatment for Alzheimer’s disease. The clinically studied chemical properties of curcumin and its various effects on AD shows the possibility to do further research and develop better drugs based on curcumin for treating AD. The recent review paper of John Ringman also supports some of the abovementioned properties of curcumin in AD.$^{[30]}$ however, large-scale human studies are required to identify the prophylactic and therapeutic effect of curcumin.

Several unanswered questions remain: What is the one main chemical property of curcumin that can be exploited in treating AD? What is the role of curcumin in other neurological disorders such as Parkinson’s, Huntington’s and other dementias? How does curcumin interact with neuronal plaques? Is it effective only as a food additive? Would it be effective when used alone or with other anti inflammatory drugs?

**References**

1. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365-75.
2. Bamberger ME, Landreth GE. Inflammation, apoptosis and Alzheimer’s disease. Neuroscientist 2002;8:276-83.
3. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, et al. Progression of clinical deterioration and pathological changes in patients with Alzheimer’s Disease evaluated at biopsy and autopsy. Arch Neurol 1999;56:1254-61.
4. Shishodia S, Sethi G, Aggarwal BB. Getting back to roots. Ann NY Acad Sci 2005;1056:206-17.
5. Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med 1991;57:1-7.
6. Youssef KM, El-Sherbeny MA. Synthesis and antitumor activity of some curcumin analogs. Arch Pharm (Weinheim) 2005;338:181-9.
7. Kolev TM, Velcheva EA, Stamboliyska BA, Spiteiller M. DFT and experimental studies of the structure and vibrational spectra of curcumin. Int J Quantum Chem 2005;102:1069-79.
8. Payton F, Sandusky P. Alworth NMR study of the solution structure of curcumin WL PMID: 17315954(Pub Med).
9. Pandav R, Belle SH, DeKosky ST. Apolipoprotein E polymorphism and Alzheimer’s disease: The Indo-US cross-national dementia study. Arch Neurol 2000;57:824-30.
10. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006;164:898-906.
11. Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2006;10:1-7.
12. Ambegaokar SS, Wu L, Alamshahi K, Lau J, Jazayeri L, Chan S, et al. Curcumin inhibits dose-dependently and time-dependently neurogal proliferation and growth. Neuro Endocrinol Lett 2003;24:469-73.
13. Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 2004;91:1199-210.
14. Pendurthi UR, Rao LV. Suppression of transcription factor Egr-1 by curcumin. Thromb Res 2000;97:179-89.
15. Park SY, Kim DS. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: A drug
discovery effort against Alzheimer's disease. J Nat Prod 2002;65:1227-31.
16. Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, Moon DO. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-B as potential targets. J Immunol 2001;174:8116-24.
17. Rathore P, Dohare P, Varma S, Ray A, Sharma U, Jaganathan NR, et al. Curcuma oil: Reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res 2007 Oct 23.
18. Jiang J, Wang W, Sun YJ, Hu M, Li F, Zhu DY. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 2007;59:54-62.
19. Frautschy SA, Hu W. Phenolic anti-inflammatory antioxidant reversal of b induced cognitive deficits and neuropathology. Neurobiol Aging 2002;21:993-1005.
20. Bala K, Tripathy BC, Sharma D. Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology 2006;7:81-9.
21. Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 2001;303:57-61.
22. Myhri RB, Jagatha B, Pradhan N, Andersen J, Bharath MM. Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? Antioxid Redox Signal 2007;9:399-408.
23. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, Motterlini R. Caffeic acid, phenethyl ester and curcumin: A novel class of heme oxygenase 1 inducer. Mol Pharmacol 2002;61:554-61.
24. Jeong GS, Pai HO, Jeong SO, Kim YL, Shin MK, Seo BY, et al. Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression: Ortho-methoxy groups are essential to enhance heme oxygenase activity and protection. Exp Mol Med 2006;38:393-400.
25. Calabrese V, Butterfield DA, Stella AM. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: Novel targets for neuroprotection in Alzheimer's disease. Ital J Biochem 2003;52:177-81.
26. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901.
27. Ono K, Hasegawa K, Naiki H, Yamada MJ. Curcumin has potent anti-amylodogenic effects for Alzheimer's beta fibrils in vitro. Neurosci Res 2004;75:742-50.
28. Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrs T, et al. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimers disease? Chem Med Chem 2008;3:165-72.
29. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacscki BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007;102:1095-104.
30. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimers disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 2007;104:12849-54.
31. Perry G, Sayre LM, Atwood CS, Castellani RJ, Cash AD, Rottkamp CA, et al. The role of iron and copper in the aetiology of neurodegenerative disorders. CNS Drugs 2002;16:339-52.
32. Dai, Xueling; SUN, Yaxuan; JIANG, Zhaofeng Copper (2) potentiation of Alzheimer's A-(beta)1-40 cytotoxicity and transition on its secondary structure. Acta Biochimica et Biophysica Sinica 1938;11:765-72.
33. Liu G, Huang W, Moir RD, Vanderburg CR, Barry AI, Zicheng P, et al. Metal exposure and Alzheimers pathogenesis. J Structural Biol 2005;155:45-51.
34. Daniel S, Limson JL, Dairam A, Watkins GM, Daya S. Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead-induced tissue damage in rat brain. J Inorg Biochem 2004;98:266-75.
35. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. Alzheimer's Dis 2004;6:367-77.
36. Shukla PK, Khanna VK, Khan MY, Srimal RC. Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol 2003;22:653-8.
37. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: The cholesterol connection. Nat Neurosci 2003;6:345-51.
38. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol in human volunteers. Indian J Physiol Pharmacol 1999;36:273-5.
39. Ireson CR, Jones DJ, Orr SL. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11.
40. Cheng AL, Hsu CH, Lin JK. Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-906.
41. Liddle M, Hull C, Liu C, Powell D Contact urticaria from curcumin. Dermatitis 2006;17:196-7.
42. Chainani N. Safety and anti-inflammatory activity of Curcumin component of turmeric (curcuma longa). J Alter Compl Med 2003;9:161-8.
43. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6.
44. Rasayid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: An ultrasound study. Aliment Pharmacol Ther 1999;13:245-9.
45. Rasayid A, Rahman AR, Jaalam K, Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 2002;11:314-8.
46. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM The curry spice curcumin reduces oxidative damage and amyloid pathogenesis on Alzheimer’s transgenic mouse. J Neurosci 2001;21:8370-7.
47. Wu A, Ying Z, Gomez-Pinilla F, Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity and cognition. Exp Neurol 2006;197:309-17.
48. Suri AA. The anti-oxidative effects of curcumin on memory curves of planaria: A model for the treatment of Alzheimer’s disease. Neurology 2003, p. S1425. Available from: http://www.usc.edu.
49. Jorm AF, Jolly D. The incidence of dementia: A meta analysis. Neurology 1998;51:728-33.
50. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2005;2:131-6.